

**OECD HIGH-LEVEL FORUM – MEDICINES FOR NEGLECTED AND EMERGING
INFECTIOUS DISEASES: POLICY COHERENCE TO ENHANCE THEIR AVAILABILITY**

**Hotels van Oranje, Noordwijk-aan-Zee, The Netherlands
20–21 June 2007**

DRAFT PROGRAMME

***We feel greatly honoured that Her Majesty Queen Beatrix of the Netherlands
has agreed to attend the High Level Forum in the morning of 21st June 2007***

WEDNESDAY, 20 JUNE 2007

19:00–22:30

Meet and Greet Session

Registration and cocktail for participants

19:30

Speakers' dinner – Hermitage Salon

THURSDAY, 21 JUNE 2007

Breakfast Buffet / Registration for late-arrivals until 08:05. All guests must be seated by 08:20

08:30

Arrival of Her Majesty the Queen

08:30–09:10

KICK-OFF SESSION

Introduction

Bert KOENDERS

Minister for Development Co-operation, The
Netherlands

“Setting the Scene”

Angel GURRÍA

OECD Secretary-General

“An African Perspective”

Antionette SAYEH

Minister for Finance, Liberia

09:10–10:15

**SESSION 1: THE ECONOMICS OF FIGHTING INFECTIOUS
DISEASES**

Chair: *Angel GURRÍA*, OECD Secretary-General

Harvey RUBIN

University of Pennsylvania, Institute for Strategic
Threat Analysis and Response, United States

Tido von SCHOEN-ANGERER

Médecins Sans Frontières, Switzerland

Hannah KETTLER

Bill and Melinda Gates Foundation, United States

Ruth LEVINE

Center for Global Development, United States

Adrian TOWSE

Office of Health Economics, United Kingdom

Speakers to address:

- Why do OECD countries have economic interests in addressing poverty related diseases that predominately affect developing countries?
- What factors could change the economic consequences of infectious disease (globalisation, ageing, climate change)?
- Can we forecast demand for treatment and prevention in the developing world?
- What are the trends on R&D for infectious diseases that predominately affect developing countries?
- What level investment in R&D is necessary to generate safe and effective new drugs/vaccines/diagnostics for infectious diseases that predominately affect developing countries?

10:15–10:50

COFFEE BREAK FOR ALL PARTICIPANTS, IN THE PRESENCE OF HER MAJESTY THE QUEEN IN THE “IMPERIAL BAR”

(Departure of Her Majesty the Queen from the Hotel at around 10.50)

11:00–12:00

SESSION 2: CREATING INCENTIVES FOR R&D INVESTMENTS: THE POLICY OPTIONS

Chair: *Howard ZUCKER*, Assistant Director-General, Health Technology and Pharmaceutical, WHO, Switzerland

<i>Michael KREMER</i>	Harvard University, United States
<i>Carlos MONTICELLI</i>	Ministry of Economics and Finance, Italy
<i>Julian SCHWEITZER</i>	The World Bank, United States
<i>Suresh JADHAV</i>	Serum Institute of India, India
<i>José Francisco GARCIA-BUSTOS</i>	GlaxoSmithKline, Spain
<i>Amit SACHDEV</i>	Biotechnology Industry Organisation, United States

Moderated roundtable discussion: The past ten years has seen the birth of a large number of “push and pull” mechanisms to promote research and development for diseases that affect the developing world including: advance purchase commitments; public private partnerships for medicine development; global purchase funds; prizes; philanthropic R&D institutes; and international technology transfer networks. This session focuses on the ability of these policy mechanisms to deliver a sustainable pipeline of new products and to create new R&D capacity globally.

- What is the measure of success for these mechanisms and what has been their record?
- Which are likely to accelerate the development of safe, effective and affordable medicines for diseases that disproportionately affect developing countries?
- Which are economically sustainable over the long term?
- Which are helping to create a competitive climate for R&D?
- Can they build R&D capacity globally? Do laboratories and companies in developing countries participate?

12:00-12:05 *Welcome on behalf of City Council of Noordwijk by the Mayor* -- Harry GROEN

12:05-12:20 *Drinks offered by the City Council of Noordwijk – Imperial Bar*

12:30-13:45 *BUFFET LUNCH – for all participants in the Oranje Nassau Windsor*

Lunch by invitation – Ministers' lunch hosted by *Ab KLINK*, Minister of Health, Welfare and Sport, The Netherlands – **Hermitage Salon**

14:00–15:00 **SESSION 3: NEW DRUGS FOR INFECTIOUS DISEASES:
IMPROVING R&D EFFICIENCY**

Chair: *Octavi QUINTANA-TRIAS*, Director, Directorate for Health, DG Research, European Commission, Belgium

Solomon NWAKA WHO/Special Programme for Research and Training in Tropical Diseases (TDR), Switzerland

Ted BLANCO Wellcome Trust, United Kingdom

Bernard PÉCOUL Drugs for Neglected Diseases Initiative, Switzerland

Harvey BALE International Federation of Pharmaceutical Manufacturers Association, Switzerland

Robert SEBBAG Sanofi-Aventis, France

Joe FECZKO Pfizer, United States

Moderated roundtable discussion: New models of innovation – including PDPs, networks, and philanthropic R&D institutes – have the potential to increase the efficiency of the research and development cycle. Can existing strategies be scaled up or new models be piloted? This session examines opportunities to radically accelerate drug/vaccine/diagnostic development for infectious diseases.

- Is a new, more efficient innovation model emerging that will address the needs of small developing country health markets?
- How can we deliver a robust pipeline of new safe and effective products that meet required profiles for infectious diseases?
- How can we better exploit existing innovative drug development capacity in the OECD and encourage investment in such capacity in developing countries?
- What sorts of infrastructures and R&D are required to support new more efficient innovation models?
- How could the prioritisation, coordination or networking of R&D activities in infectious diseases accelerate drug/vaccine/diagnostic development?

15:00–16:15

**SESSION 4: BUILDING POLITICAL SUPPORT FOR A WAY
FORWARD: THE NOORDWIJK MEDICINES AGENDA**

Chair: *Richard MANNING*, Chair of the Development Assistance Committee, OECD

OECD Members

Netherlands	<i>Ab KLINK</i> , Minister of Health, Welfare and Sport or <i>Bert KOENDERS</i> , Minister for Development Co-operation
Belgium	<i>Bruno GRyseELS</i> , Director, Institute for Tropical Medicine
Canada	<i>Abby HOFFMAN</i> , Executive Coordinator Pharmaceuticals Management Strategies/Associate ADM, Health Canada
France	<i>Didier HOUSSIN</i> , Director General of Health, Ministry of Health, Youth and Sports
Germany	<i>Frank SCHMIEDCHEN</i> , Government Director, Ministry for Economic Cooperation and Development
Mexico	<i>Gerardo JIMENEZ-SANCHEZ</i> , Director-General, National Institute of Genomic Medicines
Poland	<i>Boleslaw PIECHA</i> , Secretary of State, Ministry of Health
United Kingdom	<i>Owen BARDER</i> , Director of Global Development Effectiveness Department for International Development

non-Members

Cameroon	<i>Urbain OLANGUENA AWONO</i> , Minister of Public Health
Kenya	<i>Tom MBOYA OKEYO</i> , Counselor Medical in the Permanent Mission of the Republic of Kenya to the United Nations
Liberia	<i>Antoinette SAYEH</i> , Minister of Finance
Sudan	<i>Abdall SID AHMED</i> , Under Secretary, Federal Ministry of Health
Tanzania	<i>David MWAKYUSA</i> , Minister for Health
Thailand	<i>Prasit PALITTAPONGARNPIM</i> , Deputy General, National Center for Genetic Engineering and Biotechnology

Other Organisations

African Union	<i>Bience GAWANAS</i> , Commissioner, Social Affairs
European and Developing Countries Clinical Trials Partnerships	<i>Pascoal MOCUMBI</i> , High Representative, Ex-Prime Minister of the Republic of Mozambique

This high level governmental session will comment on the proposed “Noordwijk Medicines Agenda.” Participants will discuss how to build political support for a strategy to improve the availability of drugs/vaccines/diagnostics for neglected diseases and the challenges to building policy coherence.

- Why do OECD countries have economic interests in addressing poverty related diseases that predominately affect developing countries?
- Should there be a global strategy to accelerate research and development in infectious diseases that primarily affect developing countries? How can countries contribute to it?
- How can we mobilize resources for investment in R&D for infectious diseases?
- How can we make sure that new drugs/vaccines/diagnostics are appropriate and affordable?
- How do we bridge the solutions for making products “available” with the solutions to keeping them “affordable”?

16:15–16:45

COFFEE BREAK – IMPERIAL BAR

16:15–16:45

Press Conference – Windsor Salon

16:45–17:30

CONCLUDING REMARKS

Ab KLINK, Minister of Health, Welfare and Sport, The Netherlands

Bert KOENDERS, Minister for Development Co-operation, The Netherlands

Anarfi ASAMO-A-BAAH, WHO Deputy Director General

Angel GURRÍA, OECD Secretary-General

Closure of the Forum